Dallas-Fort Worth, Texas  ·  Founded Jan 2026

Precision Revenue
Intelligence
for Healthcare

For Labs, Specialty Practices & Value-Based Care

Ardia Health's AI engine reasons about clinical documentation to recover lost and wrongfully denied revenue — not just flagging errors, but explaining exactly why revenue was denied and generating evidence-backed recovery arguments.

$12BLab Revenue Left Unpaid
27%Avg Molecular Denial
65%Denials Never Appealed
89%Appeal Win Rate
 Open Live Dashboard See Solutions
Ardia Clinical Revenue Intelligence Engine · Live
Genomic Analysis — Patient ID-78234

Biomarkers: EGFR L858R mutation, PD-L1 75%

Recommendation: Osimertinib + Pembrolizumab combo

94% Confidence · MolDX Compliant
Denial Detected — G0480 Drug Screen

Payer: Medicare Advantage · Palmetto GBA

Denial: CO-50 Medical Necessity Not Established

Amount at Risk: $127.50

Analyzing LCD L38016...
Recovery Narrative Generated
  • Oxycodone 10mg BID prescribed (documented)
  • Screen result: Negative for opiates
  • Inconsistent finding — definitive test medically necessary
Ready to Appeal — Est. Recovery $127.50
$3.8B in lab revenue cut by PAMA since 2018
27% average molecular claim denial rate
80%+ of tox billing errors from documentation failures
$4.1B MSSP shared savings in 2024
$70B+ AI in RCM by 2030 · 24% CAGR
12,294 ASCs nationally · 57.9% physician-owned
$537B precision medicine market by 2035
$3,000 per member/year from missed HCC codes
$3.8B in lab revenue cut by PAMA since 2018
27% average molecular claim denial rate
80%+ of tox billing errors from documentation failures
$4.1B MSSP shared savings in 2024
$70B+ AI in RCM by 2030 · 24% CAGR
12,294 ASCs nationally · 57.9% physician-owned
$537B precision medicine market by 2035
$3,000 per member/year from missed HCC codes

The Only AI Built for
Healthcare Revenue Recovery

We're not a billing software. We're not an alert system. We're a clinical reasoning engine that understands payer logic from the inside.

Clinical Reasoning, Not Alerts

Our engine reads clinical documentation, cross-references payer-specific LCD rules, and generates a mechanistic explanation for every denial — then builds the evidence-backed recovery argument.

Payer-Side Insider Knowledge

12+ years at Cigna, UnitedHealth, Optum, and Teladoc. We know exactly how denial logic is constructed from the inside — giving us a unique advantage in defeating it.

Zero-Risk Contingency Model

We earn 15–20% of recovered revenue only when you succeed. No upfront cost. No implementation fees. ROI is visible within 30 days of deployment.

$118 → $2.50 Per Appeal

Manual appeals cost $118 and succeed 45% of the time. Ardia costs $2.50 and succeeds at 68–89% — a 47× cost reduction at nearly double the success rate.

Precision Medicine + Revenue

The only platform combining genomic intelligence with reimbursement intelligence. We make precision medicine economically sustainable — MolDX, Z-codes, and 400+ PLA codes.

Salesforce Health Cloud Native

HIPAA-compliant from day one. AppExchange distribution to 150,000+ healthcare organizations. 60–70% faster development with 12 Salesforce certifications.

Full Story: Why Ardia is Different

Why Ardia Wins Where Others Fail

The RCM space is crowded with alerting tools, billing software, and generic AI. Ardia is the only platform that reasons, argues, and proves — built by people who designed the denial systems it defeats.

Capability Quest / LabCorp RCM Generic AI (Olive, Waystar) Traditional RCM Vendors ⚡ Ardia Health
Clinical Reasoning (not just flagging)
Lab-Specific Denial Logic (LCD/NCD)
Partial
Auto-Generated Appeal Narratives
Generic only
Pharmacogenomics + MolDX Reimbursement
Zero-Risk Contingency Pricing
Rare
TX SB 1188 + TRAIGA Compliant by Design
Built by Former Payer Insiders (Cigna/UHC)
🧠
Insider Intelligence
12+ years inside Cigna, UnitedHealth, Optum. We built the denial logic — now we defeat it. No other AI vendor has this unfair advantage.
⚖️
Financial Adversary Engine
We don't alert you — we argue your case. Every appeal includes clinical citations, LCD cross-references, and a mechanistic proof of medical necessity.
🧬
Precision + Revenue Together
The only platform combining genomic intelligence with reimbursement logic. PGx, MolDX, Z-codes, 400+ PLA codes — all in one engine.
🛡️
Zero-Risk. Pay on Recovery.
15–20% contingency only when you recover. No upfront costs. No implementation fees. ROI visible in 30 days. If we don't win, you don't pay.

End-to-End: From Denied Claim
to Recovered Revenue

Six automated steps. No manual review. No template letters. Clinical reasoning powered by AI at every stage — from raw denial data to payer-formatted appeal in under 90 seconds.

1
Data Ingestion
Claim & Denial Intake
835/837 EDI denial files ingested via API, SFTP, or direct upload. 1,000+ claims parsed per minute. No EHR integration required for Phase 1.
ANSI X12 835837P/ISFTP / API
2
Rules Engine
Payer Rules Activation
Engine identifies exact MAC jurisdiction, applicable LCD/NCD, and denial reason code. 400+ payer policies. Updated weekly via CMS feeds.
All 7 MACsMolDXLCD/NCD
3
AI Clinical Reasoning
Document Analysis & Gap Detection
Claude AI (Anthropic) reads clinical notes, Rx, lab results, and genomic reports — then reasons against the payer's specific medical necessity criteria and pinpoints exactly what's missing.
Claude AIFHIR R4NLPHL7
4
Evidence Generation
Appeal Package Assembly
Complete appeal letter with clinical argument, LCD citations, NCCN/ASCO guideline references, and supporting documentation — formatted to the payer's exact requirements.
NCCN / ASCOAHA / ACC< 90 sec
5
Workflow & Submission
Review Queue & Direct Submission
Prioritized reviewer queue by recovery amount and deadline. One-click approval and direct clearinghouse submission. Auto-submit above configurable confidence threshold with physician attestation.
ClearinghouseAuto-Submit 85%+
6
Analytics & Learning
ROI Tracking & Continuous Learning
Every outcome tracked — paid, denied, adjusted. Real-time ROI dashboard. Successful appeals continuously refine reasoning models. Systemic denial patterns identified and exploited over time.
Real-time ROIPattern DetectionML Feedback
< 90 sec
Full Appeal Generated
$2.50
vs $118 Manual Cost
47×
Lower Appeal Cost
30 days
Time to First ROI
Full Technical Process Details

A $70B+ Market with No AI-Native
Incumbent for Independent Labs

The AI in RCM market grows at 24% CAGR. Independent labs are completely unserved.

🧠
$70B+
AI RCM Market 2030
From $20.6B in 2024 · 24% CAGR
🧬
$3.4B
Molecular Revenue at Risk
Annual denials & write-offs
💊
$537B
Precision Med Market 2035
16.3% CAGR · AI subset 38.7%
🏥
$1T+
Healthcare Revenue Lost/Year
To documentation gaps, not fraud
See Full Market Analysis & Investor Materials
Precision Medicine & Genomic Billing

Precision Medicine Revenue Intelligence

Pharmacogenomics, NGS, and molecular diagnostics are the fastest-growing — and highest-denial — segment of clinical lab testing. Ardia's MolecuIQ™ module is the only AI platform purpose-built for precision medicine reimbursement.

$120B
Precision Med TAM (2025)
Projected $250B by 2030
35.3%
Molecular Dx Denial Rate
XiFin 2024 · 20M+ claims analyzed
2.76×
Higher Denial for Ind. Labs
vs. hospital labs · JAMA 2025 n=29,919
75K+
Genetic Tests, <200 CPT Codes
Root cause of precision med denials
🧬

MolDX / DEX Z-Code Automation

Full automation of MolDX DEX Z-code assignment and validation across all 28+ states. Zero manual Z-code lookup. Every molecular diagnostic claim checked for coverage before submission.

💊

Pharmacogenomics (PGx) Prior Auth

AI-managed PGx prior authorization across all major payers. Payer-specific rules, clinical evidence matching, and automated submission — reducing PGx prior auth denial rates by 60–80%.

🔬

NGS / Next-Gen Sequencing RCM

NCCN guideline-to-diagnosis alignment checking for every NGS claim. LLM generates peer-reviewed clinical evidence citations in the appeal brief language payers respond to.

⚗️

CPT Mapping: 75,000+ Genetic Tests

Ardia's proprietary genetic test-to-CPT mapping database covers 75,000+ genetic tests mapped to the correct billing codes — eliminating the ambiguity that causes most molecular diagnostic denials.

🛡️

847-Rule Symbolic Policy Engine

Every LCD/NCD/MolDX policy encoded as deterministic logic. The symbolic engine checks each precision medicine claim against applicable coverage criteria — 100% rule coverage, zero hallucinations.

📄

AI Appeal Briefs in <90 Seconds

LLM clinical reasoning generates payer-specific, NCCN-aligned appeal letters with peer-reviewed citations in under 90 seconds — what a specialist biller takes 2–4 hours to write manually.

Full Precision Medicine Platform All Solutions
LIVE PRODUCT DEMO — INTERACTIVE

See Exactly What We Built

This is Ardia's live denial intelligence dashboard — not a mockup. Click through it, run the 90-second trial, and see the AI reasoning engine in action.

✓ PHASE 1 — ACTIVE DEVELOPMENT ✓ DFW PILOT TARGET: Q2 2026 ✓ PRE-REVENUE · SEED STAGE
ardiahealthlabs.com/dashboard.html LIVE
Open Full Screen ↗
Pilot Dashboard
Live denial queue, recovery trends, AI narrative builder, MAC LCD cross-reference
Open Dashboard →
Mobile App Preview
iOS/Android claim management — real-time denial alerts, appeal status, revenue tracking on-the-go
View Mobile App →
90-Second Free Trial
Paste any denied claim. Watch the AI reasoning engine generate a clinical appeal brief in real time
Try Free Trial →

Current Development Stage: Ardia is pre-revenue, seed stage, founded January 2026. The dashboard above is a functional prototype demonstrating the AI denial intelligence engine architecture. ToxIQ™ and MolecuIQ™ are in active Phase 1 development targeting Q2 2026 DFW pilot launch. AcoIQ™ and BehaviorIQ™ are on the 2027 roadmap.

PRODUCT SCREENSHOTS

What the Platform Looks Like

Three products. Three screenshots. Built for independent labs, molecular diagnostics, and specialty practices. View full demo gallery →

Dashboard Mobile App AI Trial
ardiahealthlabs.com/dashboard.html LIVE Open Full ↗
Ardia Health Denial Intelligence Dashboard screenshot — showing $47,280 revenue recovered, 89% appeal win rate, denial code breakdown, and live activity feed

ToxIQ™ + MolecuIQ™ Denial Intelligence Dashboard · Phase 1 Active · Open live interactive demo →

View Full Product Demo Gallery
Products & Development Stage

Four AI Modules. One Platform. Zero Risk.

Each Ardia module targets a specific, high-complexity billing segment where AI delivers the highest value. Labs pay only a 15% success fee on recovered revenue — zero upfront cost.

Pre-Revenue · Seed Stage DFW Pilot Target: Q2 2026 Founded January 2026 · Delaware LLC · Argyle, TX
ToxIQ™
Toxicology Revenue Intelligence
PHASE 1 · Q2 2026

AI-driven denial prevention and appeal automation for urine drug screening (G0480–G0483) and definitive drug testing (80300–80377 CPT codes). Highest-volume denial segment for independent labs.

Medical necessity validation per payer LCD
Quantity limits & frequency checking
Presumptive-to-definitive bundling compliance
Automated appeal brief generation
STATUS: Architecture complete  |  DFW pilot outreach active  |  Primary Phase 1 module
MolecuIQ™
Molecular Diagnostics & Precision RCM
PHASE 1 · PRIMARY

Full MolDX/DEX Z-code automation, CPT mapping for 75,000+ genetic tests, NGS prior authorization, and PGx claims processing. The most complex and highest-value billing module in lab medicine.

MolDX DEX Z-code assignment automation
PGx prior auth management all payers
NGS NCCN guideline alignment checking
AI appeal with clinical evidence citations
STATUS: Architecture complete  |  Primary flagship module  |  DFW molecular labs targeted Q2 2026
AcoIQ™
ACO Shared Savings Optimization
PHASE 2 · 2027

HCC risk adjustment coding optimization and shared savings attribution under MSSP Enhanced Track and ACO REACH programs. Targets DFW-area ACOs and value-based care organizations.

HCC coding gap identification & documentation
Shared savings attribution modeling
MSSP Enhanced / ACO REACH compliance
STATUS: Design phase  |  Phase 2 roadmap 2027  |  Texas ACO market entry
BehaviorIQ™
Behavioral Health & Addiction Medicine
PHASE 3 · 2027–28

Specialized billing for behavioral health and addiction medicine covering H-codes, J-codes (MAT), and CCBHC billing. DFW has 40+ behavioral health organizations as Phase 3 targets.

MAT J-code billing (buprenorphine, naltrexone)
CCBHC comprehensive billing optimization
SUD treatment billing & appeals automation
STATUS: Roadmap phase  |  Phase 3 target 2027–2028  |  DFW behavioral health market
🎯 Try the Platform — Interactive Demo Available Now

Explore Ardia's live dashboard showing real-time denial analysis, MAC LCD cross-reference, and recovery narrative generation. Also available: mobile app demo for on-the-go claim management.

Open Live Dashboard Mobile App Preview PLG Sandbox
Team & Founders

Built by the People Who Know the Problem From Both Sides

Our founders bring together two complementary areas of deep expertise — the technical architect who builds the AI and the payer insider who built the denial logic Ardia defeats.

Ram Vadlamudi
Founder & Product Designer / Enterprise Architect
MAIN TECHNICAL PERSON HEALTHCARE AI EXPERT

Ram is the technical founder and main builder — actively designing, building, and improving the Ardia platform daily. He invented the Neuro-Symbolic Sandwich Architecture and is the primary person executing all product development.

Platform architecture & product design (active daily)
Neuro-Symbolic Sandwich Architecture — Ardia's core AI
FHIR/HL7 interoperability & clinical data pipelines
Healthcare AI, RCM & GCP implementation (Vertex AI)
Based in Argyle, TX — 15 min from top pilot prospect
Manasa Jampani
Co-Founder & CEO
AI BACKGROUND PAYER INSIDER 12+ YEARS PAYER XP

Manasa leads all business strategy, GTM, and investor relations. With 12+ years inside payer systems at Cigna, UnitedHealth Group, Optum, and Teladoc Health, she helped build the denial logic that Ardia's AI now defeats. Her AI background and payer insider knowledge is Ardia's unparalleled competitive advantage.

CEO — business strategy, GTM, investor relations
12+ years: Cigna, UnitedHealth, Optum, Teladoc
AI background: clinical ops & payer strategy
Built payer denial logic — now helps defeat it
Actively looking to build & improve product design
✉ founders@ardiahealthlabs.com
📞 (469) 499-6435
Full Team & Company Story
🏢
Company
Ardia Health Labs LLC
Delaware LLC
📅
Founded
January 2026
DFW Pilot · Q2 2026
📍
Headquarters
Argyle, TX 76226
Dallas-Fort Worth Metro
☁️
Infrastructure
Google Cloud Platform
Vertex AI · Healthcare Data Engine

Ardia Health Labs LLC  ·  ardiahealthlabs.com  ·  founders@ardiahealthlabs.com  ·  Pre-Revenue · Seed Stage · Building on Google Cloud

See the Engine in Action

Interactive dashboard showing real-time denial analysis, MAC LCD cross-reference, and recovery narrative generation.

Open Live Dashboard Schedule Demo